Tempus AI Inc (Tempus AI (TEM)) is having a good Thursday. Shares are up more than 8% after the company announced a major expansion of its AI-powered Next platform, just in time for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

The Next platform is designed to do something that sounds simple but is actually pretty hard: give doctors real-time insights into patient data, rather than relying on old, retrospective analyses. Think of it as moving from looking in the rearview mirror to having a GPS that updates every second.

Tempus says the platform now covers six new clinical scenarios, including breast, colorectal, ovarian, prostate, and urothelial cancers. It also added advanced intelligence features that let precision medicine teams map out patient experiences and create targeted programs to close care gaps.

The timing is no accident. At ASCO 2026, Tempus will present a study showing how the platform improved biomarker testing rates for early-stage non-small cell lung cancer (eNSCLC). That's a big deal because biomarker testing is critical for matching patients with the right therapies, but it often gets missed in the chaos of real-world care.

Ryan Fukushima, CEO of Data and Apps at Tempus, put it this way: “The true challenge in precision oncology is the data fragmentation that hides critical care gaps across the patient journey. By expanding Next, we are providing our health systems partners with a 360-degree view to not only identify these gaps but to quantify the truly addressable opportunities for intervention.”

In plain English: the platform sifts through messy electronic health records to find patients who aren't getting the tests they need, and then helps hospitals do something about it.

So what does this mean for the stock? TEM is trading at $51.11, up 8.36% on the day. That puts it above its 20-day and 50-day moving averages, which is a short-term positive. Dip-buyers are showing up, and the RSI sits at 45.66 — not oversold, but not overbought either.

But the longer-term picture is still a work in progress. Shares are 5.5% below the 100-day SMA and 22.9% below the 200-day SMA. The 20-day SMA is still below the 50-day SMA, and the death cross that triggered in January (50-day below 200-day) hasn't been resolved. So this is more of a repair phase than a full-on breakout.

From a level-to-level standpoint, the stock is well off its 52-week high of $104.32 and closer to the lower end of its range. Key resistance is at $56.50, and key support is at $42.50.

For now, the market is cheering the platform expansion and the upcoming ASCO data. Whether that momentum holds will depend on how the real-world results land with investors and, ultimately, with the health systems that might buy the product.